<span item_type="fundamental" item_id="bc93b78d2d3a36e32d7a9ff11bd71508" counter_id="ST/US/CPIX" env="prod"></span><span item_type="announcement" item_id="579189359894463489" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 8.292 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.13.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -1.987 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Third Quarter 2025</strong>: Total net revenue was $8.3 million, with contributions from Kristalose® ($1.2 million), Sancuso® ($3.2 million), Vibativ® ($2.6 million), and Caldolor® ($0.9 million).</li><li><strong>Year-to-date 2025</strong>: Total net revenue was $30.8 million, with Kristalose® contributing $7.4 million, Sancuso® $8.6 million, Vibativ® $6.7 million, and Caldolor® $3.8 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000108729425000017/a2025q3-ex991er.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Operating Expenses</strong>: $10.3 million for the third quarter and $32.3 million year-to-date 2025.</li><li><strong>Net Income (Loss)</strong>: - $1.9 million for the third quarter and - $1.4 million year-to-date 2025.</li><li><strong>Adjusted Earnings</strong>: - $0.8 million, or - $0.06 per share for the third quarter; $1.9 million, or $0.13 per diluted share year-to-date 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000108729425000017/a2025q3-ex991er.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Provided by Operating Activities</strong>: $4.9 million.</li><li><strong>Net Cash Used in Investing Activities</strong>: - $1.6 million.</li><li><strong>Net Cash Used in Financing Activities</strong>: - $6.1 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000108729425000017/a2025q3-ex991er.htm"></span></li></ul><h3>Balance Sheet (as of September 30, 2025)</h3><ul><li><strong>Total Assets</strong>: $66 million.</li><li><strong>Cash and Cash Equivalents</strong>: $15 million.</li><li><strong>Liabilities</strong>: $40 million.</li><li><strong>Shareholders’ Equity</strong>: $26 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000108729425000017/a2025q3-ex991er.htm"></span></li></ul><h3>Outlook / Guidance</h3><p>Cumberland Pharmaceuticals Inc. is focused on providing unique products to improve patient care and is encouraged by the progress of its development programs for orphan patient populations. The company is optimistic about the potential value creation from its new commercial product, Talicia, and its international agreements for Vibativ and ibuprofen injection products.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000108729425000017/a2025q3-ex991er.htm"></span></p>

Cumberland Pharma | 8-K: FY2025 Q3 Revenue: USD 8.292 M